Celltrion's Stock Price at 232,000 Won (3.34%) with Focus on 'COVID-19 Treatment Business'

As of 9:30 AM on the 3rd, Celltrion is trading at 232,000 KRW, up 3.34% from the previous day. The trading volume is 694,985 shares, which is 63.83% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.

On June 2nd, Hyun Byung-hwa, a researcher at Eugene Investment & Securities, stated, "Celltrion, which is developing a COVID-19 antibody treatment, has produced meaningful results in animal efficacy trials. It plans to simultaneously enter Phase 1 and 2 human trials domestically and internationally between late July and August. The company has experience developing antibody treatments for influenza and MERS through CTP 27 and 38, and its production capacity is fully competitive with major global pharmaceutical companies. This adds another promising pipeline to raise expectations. After development completion, global sales of the COVID-19 antibody treatment will be handled by Celltrion Healthcare." He set Celltrion’s target price at 250,000 KRW.

Over the past five days, individual investors have net sold 212,091 shares of Celltrion, while foreign investors and institutions have net bought 394,588 shares and net sold 178,039 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.